Middle East and Africa Cell Based Assays Market, By Type (Cell Viability Assay, Cytotoxicity Assay, Cell Death Assay, Cell Proliferation Assay and Others), Product and Services (Consumables, Services, Instruments and Software), Technology (Flow Cytometry, High Throughput Screening, High Content Screening and Label Free Detection), Application (Drug Discovery, Basic Research and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutions, Government Organizations and Others), Distribution Channel (Direct and Indirect) – Industry Trends and Forecast to 2030.
Middle East and Africa Cell Based Assays Market Analysis and Size
Rising prevalence of chronic and infectious diseases globally and increasing research and development proficiencies have led to the rise in cell based assays market value. Increased focus on research and development proficiencies in regards to medical devices and on the adoption of advanced healthcare technologies, growing awareness and rising expenditure for the development of healthcare infrastructure especially in the developing economies are the major factors attributable to the growth of cell based assays market.
Data Bridge Market Research analyses that the Middle East and Africa cell based assays market which was USD 428.33 million in 2022, would rocket up to USD 1,345.75 million by 2030, and is expected to undergo a CAGR of 11.07% during the forecast period. This indicates that the market value. “Cell Based Assay” dominates the type segment of the Cell Based Assays market owing to the high demand of this type of assays. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Middle East and Africa Cell Based Assays Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Cell Viability Assay, Cytotoxicity Assay, Cell Death Assay, Cell Proliferation Assay and Others), Product and Services (Consumables, Services, Instruments and Software), Technology (Flow Cytometry, High Throughput Screening, High Content Screening and Label Free Detection), Application (Drug Discovery, Basic Research and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutions, Government Organizations and Others), Distribution Channel (Direct and Indirect)
|
|
Countries Covered
|
Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)
|
|
Market Players Covered
|
Promega Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), PerkinElmer, Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Corning Incorporated (U.S.), Cell Signaling Technology, Inc. (U.S.),
|
|
Market Opportunities
|
|
Market Definition
Cell based assays is a technology that is used for cytotoxic and biological testing. Cell based assays technology is used to conduct research and development activities or experiments using live cells. It is a homogeneous method that is used to detect the cell toxicity, proliferation, motility and other parameters. In other words, cell based assays provide a closer look to real life models by employing live cells in a sample.
Middle East and Africa Cell Based Assays Market Dynamics
Drivers
- Increasing Demand for Drug Discovery and Development
Cell-based assays play a crucial role in drug discovery and development by providing valuable insights into the efficacy, safety, and toxicity of potential drug candidates. The growing demand for innovative therapeutics and the need for efficient drug screening processes fuel the adoption of cell-based assays
- Advancements in High-Throughput Screening (HTS) Technologies
HTS technologies have revolutionized the drug discovery process by enabling the screening of large compound libraries against cellular models. The development of automated systems, robotics, and imaging techniques has enhanced the efficiency and throughput of cell-based assays, driving their adoption in pharmaceutical and biotechnology industries
- Growing Investment for Healthcare Facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities
Opportunities
- Technological Advancements
The development of advanced cell culture techniques, such as 3D cell culture models and organoids, has improved the physiological relevance and predictive power of cell-based assays. These advancements enable researchers to better mimic in vivo conditions, leading to more accurate and reliable results
-
Growing Focus on Personalized Medicine
Personalized medicine aims to tailor medical treatments to individual patients based on their genetic, environmental, and lifestyle factors. Cell-based assays offer a valuable platform for studying patient-specific responses to drugs, facilitating the development of personalized treatment strategies
Restraints/Challenges
- High Cost
Developing and implementing cell-based assays can be expensive due to the need for specialized equipment, reagents, and skilled personnel. The high costs associated with assay development, optimization, and validation can be a significant restraint for smaller research organizations and academic institutions
-
Lack of Standardization and Reproducibility
Ensuring the reproducibility and standardization of cell-based assays can be challenging. Variability in cell culture conditions, assay protocols, and cell lines used can lead to inconsistent results. This lack of standardization hinders the comparability and reliability of data generated from different studies, limiting the widespread adoption of cell-based assays.
This cell based assays market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cell based assays market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Developments
- In 2021, Promega launched the OncoMate™ MSI Assay, a PCR-based microsatellite instability (MSI) assay that helps identify solid tumor patients who may benefit from immune checkpoint inhibitor therapies
- In 2020, Charles River Laboratories expanded its cell-based assay portfolio by acquiring RetroScreen Virology Ltd., a company specialized in virology screening and antiviral drug discovery services
Middle East and Africa Cell Based Assays Market Scope
The cell based assays market is segmented on the basis of type, product and services, technology, application, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying market applications.
Type
- Cell Viability Assay
- Cytotoxicity Assay
- Cell Death Assay
- Cell Proliferation Assay
- Others
Product and Services
- Consumables
- Services
- Instruments
- Software
Technology
- Flow Cytometry
- High Throughput Screening
- High Content Screening
- Label Free Detection
Application
- Drug Discovery
- Basic Research
- Others
End-Users
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutions
- Government Organizations
- Others
Distribution Channel
- Direct
- Indirect
Middle East and Africa Cell Based Assays Market Regional Analysis/Insights
The cell based assays market is analysed and market size insights and trends are provided by country, type, product and services, technology, application, end-user and distribution channel as referenced above.
The countries covered in the Middle East and Africa cell based assays market report are Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)
Saudi Arabia dominates the Middle East and Africa cell based assays market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The cell based assays market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cell based assays market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Cell Based Assays market. The data is available for historic period 2010 to 2020.
Competitive Landscape and Middle East and Africa Cell Based Assays Market Share Analysis
The cell based assays market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to cell based assays market.
Some of the major players operating in the cell based assays market are:
- Promega Corporation (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- PerkinElmer, Inc. (U.S.)
- Merck KGaA (Germany)
- Bio-Rad Laboratories, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Charles River Laboratories International, Inc. (U.S.)
- Lonza Group Ltd. (Switzerland)
- Corning Incorporated (U.S.)
- Cell Signaling Technology, Inc. (U.S.)
SKU-